Phio Pharmaceuticals CEO Robert J. Bitterman Buys 10,000 Shares

What Happened

• Robert J. Bitterman, Chairman, President & CEO and a director of Phio Pharmaceuticals (PHIO), acquired 10,000 shares in an open-market purchase on August 18, 2026. The shares were bought at $1.06 per share for a total reported cost of $10,600. This was a purchase transaction (code P).

Key Details

• Transaction date: 2026-08-18; reported on Form 4 filed 2026-08-19 (appears timely).
• Price and amount: 10,000 shares at $1.06 each; total value $10,600.
• Transaction code: P = Purchase (open market/private purchase).
• Shares owned after the transaction: not specified in the provided filing summary.
• Footnote: F1 notes that reported holdings include shares of common stock underlying unvested restricted stock units (RSUs).

Context

• This was a straightforward open-market purchase (no options exercised or awards received). The $10,600 purchase is modest in dollar terms; purchases can be interpreted as a positive signal but do not by themselves prove insider confidence.